|Title||Professor, chief physician, doctoral advisor and Chief for Department of Hematology|
Prof. Lv specializes in clinical medical treatment for oncology (chemotherapy and targeted therapy) and researches on new anticancer methods and drugs, especially treatment of and research on tumors and sarcoma difficult to diagnosis such as hematological tumor (leukemia, lymphoma, myeloma and MDS).
2009-present: Chief for Department of Hematological Tumor, professor and chief physician at Sun Yat-sen University Cancer Center
Clinical diagnosis and treatment of new hematological tumor
Treatment and prevention of cancer metastasis
Cancer molecular diagnosis, gene targeted therapy and immunobiologic therapy
1982: Graduated from School of Medicine of China Medical University
1991-1996: Graduated from the 4th Department of Medicine, Affiliated Hospital of Sapporo Medical University, and was conferred upon the degree of Doctor of Medicine in Japan
Dr. Wang Liang completed his 8-year program of clinical medicine at Peking Union Medical College and was conferred upon the degree of Doctor of Medicine in 2010. He has been working at Hematological Tumor of Sun Yat-sen University Cancer Center since August 2010. He specializes in diagnosis and treatment of leukemia, myeloma, and myelodysplastic syndrome.
1. Drug resistance mechanism of chemotherapy for acute leukemia;
2. Drug resistance mechanism of NK/T-cell lymphoma;
3. Mechanism of neurotoxicity caused in myeloma patients by bortezomib.
09/2002-02/2005: Completed pre-med program at School of Life Sciences of Peking University
02/2005-07/2010: Completed the program of clinical medicine at Peking Union Medical College was conferred upon the degree of Doctor of Medicine.
First-Line Combination of Gemcitabine, Oxaliplatin, and L-Asparaginase (GELOX) Followed by Involved-Field Radiation Therapy for Patients With Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma Cancer (SCI) 5.201 2013 1Primary Pulmonary Lymphoepithelioma -Like Carcinoma: Fifty-Two Patients With Long-Term Follow-Up Cancer (SCI) 5.201 2012 1Esophageal Carcinosarcoma: A Unique Entity with Better Prognosis Ann Surg Oncol (SCI) 4.12 2013 1Expression of ezrin correlates with poor prognosis of nasopharyngeal carcinoma Tumor Biol (SCI) 2.518 2011 1Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/Tcell lymphoma Tumor Biol (SCI) 2.84 2014 1Prognostic significance of neuron-specific enolase in patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy Leukemia & Lymphoma (EI) 2.301 2011 1Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified Leukemia & Lymphoma (EI) 2.301 2011 1Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report Leukemia & Lymphoma (EI) 2.605 2013 1Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma Leukemia & Lymphoma (EI) 2.605 2014 1Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy Med Oncol (EI) 2.147 2012 1Clinical significance of serum soluble interleukin 2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): A predictive biomarker for treatment efficacy and valuable prognostic Med Oncol (EI) 2.147 2013 1Combination of gemcitabine,L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up Med Oncol (EI) 2.147 2013 1Cyclophosphamide, doxorubicin, vincristine, and prednisone(CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients Int J Hematol (EI) 1.681 2012 1Project name Start & end dates Funding entity Fund(RMB) Rank of Wang LiangExpression and significance of CD25 and soluble interleukin-2 receptor (sCD25) in extranodal NK/T-cell lymphoma (ENKTL) 11/2012-12/2015 Sun Yat-sen University 150,000 1Clinical stage II research on GELOX concurrent chemoradiotherapy for early NK/T-cell lymphoma 06/2014-06/2016 Medical Scientific Research Foundation of Guangdong Province 10,000 1Clinical stage II research on GELOX concurrent chemoradiotherapy for early NK/T-cell lymphoma 01/2014-12/2018 Sun Yat-sen University Cancer Center 250,000 1Effect and mechanism of lowering glycolytic enzyme and NSE for treatment of non-Hodgkin lymphomas (NHL) 08/2012-12/2016 National Natural Science Foundation 75 3
Dr. Geng Qi-Rong is attending doctor of Hematology and Oncology of Sun Yat-sen University Cancer Center. Dr. Geng obtained his Master of Oncology and tumor specialist qualifications at Sun Yat-sen University of Medical Sciences, P. R. China in 2006 and 2009 respectively. She studied in the department of leukemia at University of Texas MD Anderson Cancer Center as a visiting scientist between 4/2/2012 and 8/26/2013. She has been working in the department of Hematology and Oncology at Sun Yat-sen University Cancer Center as attending doctor since 2009. She is skilled at the diagnosis and management of Hematology Oncology as leukemia,multiple myeloma, lymphoma and myelodysplastic syndrome etal.
|Research Interest(s)||Interested in research about hematology oncology.|
1995-2000 ANHUI medical university Bachelor degree;
2003-2006 Sun Yat-sen University of Medical Sciences oncology master degree;
2006-2009 Sun Yat-sen University of Medical Sciences Oncology clinician
|Publications||Published several papers in Blood, PLOS ONE et al.|